News
Imunon Betting on Biomarker Subset to Quickly Bring Immune Boosting Ovarian Cancer Therapy to Market
The OVATION-3 trial is designed to provide an early readout in HRD and BRCA1/2-mutated ovarian cancer patients, ideally leading to rapid filing and approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback